Curaleaf Appoints Four 20 Pharma Founder Torsten Greif to Board, Bolstering European Strategy

summarizeSummary

Curaleaf Holdings, Inc. announced the appointment of Torsten Greif, a founder of Four 20 Pharma GmbH, to its Board of Directors, strengthening its strategic leadership for European expansion.

check_boxKey Events

• New Board Appointment

  Curaleaf Holdings, Inc. announced the appointment of Torsten Greif to its Board of Directors, effective May 1, 2026.

• Strategic Integration Post-Acquisition

  Mr. Greif is a founder of Four 20 Pharma GmbH, a German medical cannabis company in which Curaleaf recently completed the acquisition of the remaining 45% stake on April 30, 2026. His appointment directly supports the integration and strategic growth of Curaleaf's European operations.

• Expertise in European Cannabis Market

  Mr. Greif brings extensive experience in cannabis cultivation, regulatory strategy, and brand development within Germany's medical cannabis market, which is crucial for Curaleaf's international expansion.

auto_awesomeAnalysis

This appointment is a strategic move following Curaleaf's recent acquisition of the remaining stake in Four 20 Pharma GmbH. Torsten Greif, a founder of the German medical cannabis company, brings deep local market knowledge and regulatory expertise to Curaleaf's board. His addition is expected to significantly aid the integration of Four 20 Pharma and accelerate Curaleaf's expansion and operational excellence in the rapidly evolving European cannabis market.